Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) ...

On April 22, 2026, Certara, Inc. (NASDAQ:CERT) said it entered into a definitive agreement to sell its regulatory and medical ...

Certara shares rose after the company agreed to sell its regulatory and medical writing business to Veristat for up to $135 million. Shares of Certara rose 4.1% Wednesday to $6.46. The drug ...

Veristat has announced its intended acquisition of Certara's Regulatory and Medical Writing business, a move that will add ...

Certara’s updated fair value estimate has shifted from US$8.99 to US$8.71, a small reset that still sits in the same broad price target zone as recent Street moves toward roughly US$8 to US$10. Those ...

Preview this article 1 min The business unit generated $50 million in revenue last year. Malvern biopharma firm to be ...

Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of ...

Pharmaceutical biosimulation software company Certara won an R&D 100 Award from R&D World magazine for its its Simcyp COVID-19 Vaccine Model. The nearly 50-year-old worldwide competition lists the top ...

Certara (CERT) stock jumps as the company agrees to sell its regulatory & medical writing unit for up to $135M, boosting AI ...

Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of ...